Jun 27, 2022 04:28 PM (GMT+8) · EqualOcean
According to the official website of the drug evaluation center (CDE) of the State Food and Drug Administration of China, the donnemab injection clinical trial application applied by Eli Lilly has obtained an implied license to be developed for early symptomatic Alzheimer's disease, including mild cognitive impairment caused by Alzheimer's disease and mild Alzheimer's disease. Public information shows that donanemab is an anti-virus product developed by Lilly β Amyloid antibody has previously reached the primary endpoint in phase 2 clinical trials. Lilly has already started to submit a rolling application for the drug to the FDA to seek the FDA's accelerated approval. Donanemab is a β Monoclonal antibody binding to amyloid subtype n3pg. It can be linked to β Amyloid binding, thereby promoting the clearance of amyloid deposits in the patient's brain.

This text is a result of machine translation.